Stocks in focus: Glenmark Pharma, Cipla, Reliance Capital, HDFC Bank shares to remain in news today

Market sentiments would be swayed by global cues, development around geopolitical tensions, coronavirus cases, monthly F&O expiry and foreign fund movement

U.S. Stocks, Apple, Stock Split, iPhone maker, U.S. tech companies, U.S. tech stocks

Cipla, Ashok Leyland, Tata Chemicals, Escorts, agri stocks to remain in action today

Aarti Drugs, Cipla, Crompton Greaves, IIFL Securities, Nippon Life India Asset Management, Tata Chemicals and L&T Technology Services are among 12 companies that are scheduled to announce their March quarter earnings today.

Regeneron Pharmaceuticals, S&P 500, best performing stock, Netflix, Amazon,

Sun Pharma, Aurobindo Pharma among top stock picks from Pharma sector; CLSA sees gain up to 30%

Among pharma stocks, the top stock picks of CLSA are Sun Pharma, Cipla, Aurobindo Pharma and Cadila Healthcare, recommending a 'buy' rating on them

Cipla share price falls 5% after warning letter from US Food and Drug Administration

he USFDA had conducted an inspection at Cipla’s Goa facility in September last year. Cipla share price was down at Rs 406 on market opening.

Cipla board approves appointment of Dr Reddy’s Laboratories’ Kedar Upadhye as Global CFO

Drug firm Cipla today said its board has approved appointment of Kedar Upadhye as the company's Global Chief Financial Officer.

Delhi HC questions govt over urgency to ban over 300 FDC drugs

Additional Solicitor General was responding to the contentions of pharma companies like Pfizer, Glenmark, Procter and Gamble and Cipla

Delhi HC extends relief to pharma firms over drug ban

Several companies went to the Delhi High Court to try to get the ban lifted

11 stocks trending in Friday’s trade: Crompton Greaves, DLF and more

Healthcare majors, including Cipla, Lupin, Wockhardt, Glaxosmithkline and Mankind Pharma, on Thursday granted interim relief by Delhi High Court which stayed till March 21 the ban imposed by the Centre on sale of some of thei

Cipla invests additional $ 3mn in US’s Chase Pharmaceuticals

Cipla in May 2014 had invested $1.5 million to acquire 14.6 per cent stake in Chase Pharmaceuticals.


Cipla completes acquisition of generic businesses in US

The acquisition will provide a launch pad to introduce Cipla’s pipeline of products in respiratory and injectables, among others, in the coming years Cipla’s UK arm, Cipla (EU) has closed the transaction to acquire tw

Cipla posts PAT of Rs 343 crore in Q3 FY1516

Domestic sales reduced to Rs 1,194 crore Cipla announced its unaudited consolidated financial results for the quarter ended December 31, 2015 (Q3). Income from operations grew by 12.3 per cent to Rs 3,107 crore, up from Rs. 2

Cipla patriarch Y K Hamied increases stake in company to over 20 per cent

Acquires additional five per cent stake from his wife Farida Hamied In a move aimed at realignment of family shareholding, Cipla patriarch YK Hamied has increased his stake in the homegrown drug major to over 20 per cent by a

Cipla gets CCI nod to sell stake in consumer healthcare business

In November last year, the company signed an agreement to sell 26.11 per cent in Cipla Health to FIL Capital Investments (Mauritius) II Cipla has received approval from fair trade regulator CCI to sell about 26 per cent stake

SC admits Cipla’s plea for expert appointment in Hoffmann-La Roche patent row

In Nov, the Delhi HC, while holding Cipla guilty of infringing Roche’s patent over lung cancer drug Erlotinib, had held that its Erlocip violated the patent rights of Hoffman-La Roche

Top 10 stocks that trended in today’s trade: SpiceJet, Interglobe Aviation, Supreme Petrochem and more

SpiceJet shares closed 11.22 per cent up at Rs 78.80 after the company posted a net profit of Rs.238.39 crore in the December quarter, against a net loss of Rs.275.02 crore in the year-ago period.

Stocks in focus

Cipla announces new management council

Appoints Umang Vohra as its Global Chief Operating Officer Cipla announced the creation of a six member Management Council that will be the apex executive leadership team for the company. This is part of its ongoing transform

Cipla inks pact with US firm for Ropivacaine infusion system

Drug major Cipla has inked a pact with US-based BioQ Pharma for registration and commercialisation of latter's Ropivacaine infusion system, used in treating post-operative pain, in India.

Cipla stake

Cipla launches anti-ageing skin care product Cutisera

Cutisera has been developed by Stempeutics Cipla has launched a novel “5 in 1” anti-ageing skin care product Cutisera developed by Stempeutics. Cutisera has been developed using bio-active factors derived from human adult

Cipla ready to launch low-dose Efavirenz 400 mg

Studies found that the reduced dose of 400 mg Efavirenz was non-inferior to the standard dose of 600 mg Efavirenz dose

Cipla inks investment pact with FIL Capital Investment

No financial deals of the agreement were disclosed

Delhi HC tells govt not to take coercive steps against pharma cos

Petitions were filed by pharma companies and an association of medicine manufacturing firms challenging the government’s new drug pricing order that asked them to slash prices of 348 medicines The Delhi High Court has t

Cipla appoints Naina Lal Kidwai as Independent Director on its Board

She received the Padma Shri Award in 2007 from Government of India Cipla has announced the appointment of Naina Lal Kidwai as an independent director on its board effective November 6, 2015. Until recently Kidwai was Executiv

Cipla to sell entire stake in Biomab Holding for $25,775,000

Drug major Cipla has entered into an agreement to sell its entire stake in Biomab Holding to Biomab Brilliant Ltd for a consideration of USD 25,775,000 to focus on biological segment under its arm Cipla BioTec.

Cipla stake

Cipla to strengthen its focus on biotech

Divests its remaining stake in Hong Kong-based Biomab Holding to focus on global development under Cipla BioTec Cipla has entered into a definitive agreement to sell its entire 25 per cent stake in Biomab Holding Limited, Hon

Cipla’s Indore plant under US FDA scanner

As many as nine issues have been raised by the regulator under ‘Form 483’ regarding manufacturing practices in the plant Cipla’s Indore plant has come under the scanner of US health regulator for manufacturi

Cipla falls; traders cite FDA concerns over InvaGen plant

Cipla, India's fourth-largest drugmaker by sales, falls as much as 3 pct to 660 rupees.

Cipla stake
Income Tax Calculator, Budget 2019, How to Calculate Income Tax


Stock Market

Most Read


Budget 2020


Related Articles